Last Updated: August 9, 2026

Claims for Patent: 9,657,021


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,657,021
Title:Process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]-octane
Abstract:A process for preparation of (2S,5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane of Formula (I) is disclosed which is comprising reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV). Crystalline compounds of Formula (I) are claimed.
Inventor(s):Sanjeev Joshi, Karuna Suresh WANKHEDE, Sunil Bhaginath Jadhav, Shivaji Sampatrao Pawar, Vinod Kashinath AHIRRAO, Satish Bhawsar, Prasad Keshav Deshpande, Ravindra Dattatraya Yeole, Mahesh Vithalbhai Patel
Assignee: Wockhardt Ltd
Application Number:US14/769,815
Patent Claims: 1. A process for preparation of a compound of Formula (I), comprising: (a) reacting a compound of Formula (II) with a compound of Formula (III) in presence of water as solvent to obtain a compound of Formula (IV); (b) hydrogenolysis of the compound of Formula (IV) to obtain a compound of Formula (V); (c) sulfonating the compound of Formula (V) to obtain a compound of Formula (VI); (d) reacting the compound of Formula (VI) with trifluoroacetic acid to obtain a solid; and (e) dissolving the solid obtained in step (d) in a solvent and adjusting the pH between 4.5 to 5.5 to obtain the compound of Formula(I).

2. The process according to claim 1, wherein the reaction of the compound of Formula (II) with the compound of Formula (III) to obtain the compound of Formula (IV) is carried out in presence of 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.

3. The process according to claim 1, wherein the hydrogenolysis of the compound of Formula (IV) to obtain the compound of Formula (V) is carried out in presence of a transition metal catalyst and a hydrogen source.

4. The process according to claim 3, wherein the transition metal catalyst is palladium on carbon and the hydrogen source is hydrogen gas.

5. The process according to claim 1, wherein the sulfonation of the compound of Formula (V) to obtain the compound of Formula (VI) is carried out by reacting the compound of Formula (V) with sulfur trioxide—pyridine complex, followed by treatment with tetra butyl ammonium hydrogen sulfate.

6. The process according to claim 1, wherein the pH adjustment is carried out with sodium-2-ethylhexanoate.

7. A process for preparation of a compound of Formula (I) in crystalline form, comprising (a) dissolving in water the compound of Formula (I) as obtained in claim 1 to yield a clear solution; (b) adding isopropyl alcohol to the clear solution obtained in step (a) under stirring; and (c) isolating the compound of Formula (I) in crystalline form.

8. The compound of Formula (I) according to claim 7, wherein the compound has an X-ray powder diffraction pattern comprising a peak selected from the group consisting of 10.28 (±0.2), 10.57 (±0.2), 12.53 (±0.2), 13.82 (±0.2), 15.62 (±0.2), 18.16 (±0.2), 18.49 (±0.2), 20.35 (±0.2), 20.64 (±0.2), 21.33 (±0.2), 22.99 (±0.2), 23.18 (±0.2), 24.27 (±0.2), 24.81 (±0.2), 25.45 (±0.2), 29.85 (±0.2), 30.45 (±0.2), 32.39 (±0.2), and 36.84 (±0.2) degrees 2 theta.

9. The compound of Formula (I) according to claim 7, wherein the compound has an X-ray powder diffraction pattern comprising a peak selected from the group consisting of 10.28 (±0.2), 10.57 (±0.2), 12.53 (±0.2), 13.82 (±0.2), 15.62 (±0.2), 18.16 (±0.2), 18.49 (±0.2), 20.35 (±0.2), 20.64 (±0.2), 21.33 (±0.2), 24.27 (±0.2), 24.81 (±0.2), and 25.45 (±0.2) degrees 2 theta.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.